Palvella Therapeutics (PVLA) Total Non-Current Liabilities (2013 - 2026)
Palvella Therapeutics (PVLA) reported Total Non-Current Liabilities of $19.8 million for Q1 2026, down 10.57% year-over-year from $22.1 million in Q1 2025, and up 11.24% on a QoQ basis from $17.8 million in Q4 2025.
Palvella Therapeutics (PVLA) has 14 years of Total Non-Current Liabilities data on file, last reported at $19.8 million in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 10.57% year-over-year to $19.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.8 million (down 10.57% YoY) and the FY2025 annual result came in at $17.8 million, up 49.58% from the prior year.
- Total Non-Current Liabilities improved to $19.8 million in Q1 2026 per PVLA's latest filing, from $17.8 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $67.6 million in Q4 2022 and bottomed at $10.4 million in Q4 2023.
- The 5-year median for Total Non-Current Liabilities is $17.8 million (2025), against an average of $25.2 million.
- The widest annual swing landed in 2023, when Total Non-Current Liabilities tumbled 84.59%; it then jumped 49.58% in 2025.
- Tracing PVLA's Total Non-Current Liabilities over 5 years: stood at $67.6 million in 2022, then plunged by 84.59% to $10.4 million in 2023, then rose by 14.27% to $11.9 million in 2024, then jumped by 49.58% to $17.8 million in 2025, then increased by 11.24% to $19.8 million in 2026.
- Per Business Quant, the three latest PVLA Total Non-Current Liabilities figures stand at $19.8 million (Q1 2026), $17.8 million (Q4 2025), and $16.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | 19.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.80 Mn |
| Dec 31, 2025 | 17.80 Mn |
| Sep 30, 2025 | 16.00 Mn |
| Jun 30, 2025 | 14.50 Mn |
| Mar 31, 2025 | 22.14 Mn |
| Dec 31, 2024 | 11.90 Mn |
| Dec 31, 2023 | 10.41 Mn |
| Jun 30, 2023 | 47.05 Mn |
| Dec 31, 2022 | 67.56 Mn |
| Dec 31, 2021 | 102.81 Mn |
| Sep 30, 2021 | 110.33 Mn |
| Jun 30, 2021 | 108.31 Mn |
| Mar 31, 2021 | 77.55 Mn |
| Dec 31, 2020 | 73.98 Mn |
| Dec 31, 2019 | 89.75 Mn |
| Sep 30, 2019 | 84.03 Mn |
| Jun 30, 2019 | 99.04 Mn |
| Mar 31, 2019 | 100.86 Mn |
| Dec 31, 2018 | 101.38 Mn |
| Sep 30, 2018 | 101.36 Mn |
| Jun 30, 2018 | 106.67 Mn |
| Mar 31, 2018 | 122.51 Mn |
| Dec 31, 2017 | 92.32 Mn |
| Sep 30, 2017 | 94.26 Mn |
| Jun 30, 2017 | 96.58 Mn |
| Mar 31, 2017 | 43.80 Mn |
| Dec 31, 2016 | 9.79 Mn |
| Sep 30, 2016 | 12.19 Mn |
| Jun 30, 2016 | 9.12 Mn |
| Mar 31, 2016 | 9.99 Mn |
| Dec 31, 2015 | 2.80 Mn |
| Sep 30, 2015 | 2.24 Mn |
| Jun 30, 2015 | 3.02 Mn |
| Mar 31, 2015 | 2.25 Mn |
| Dec 31, 2014 | 3.85 Mn |
| Dec 31, 2013 | 6.31 Mn |